13 April 2022 - Sotorasib is a Kirsten rat sarcoma (KRAS) G12C inhibitor, which covalently and irreversibly binds to the unique cysteine of KRAS G12C.

Lumakras has provisional approval in Australia for the treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy for advanced disease.

Read TGA prescription medicine decision summary for Lumakras